SAHPRA CEO, Dr Boitumelo Semete-Makokotlela, clinched a Management Award at last night’s 24th National Science and Technology Forum (NSTF) Awards, that recognises outstanding contributions to science, engineering and technology (SET), and innovation.
According to NSTF, Dr Semete-Makokotlela earned her accolade as “she successfully led the authorisation of a number of COVID-19 diagnostic tests, vaccines and therapies during the COVID-19 pandemic, is a sterling testament to her drive and passion to ensure that the regulator is an enabler”.
Dr Semete-Makokotlela was up against some worthy nominees within the Management category from various South African universities across the country. The other categories included: scientific research, innovation, SET management and related activities, capacity development in engineering research, environmental sustainability and biodiversity conservation, water research and innovation, data for research, and science communication.
The Head of SAHPRA praised and acknowledged her family, her team and Board for their support and commitment as her victory is not only reflective of her leadership and drive but the abilities, dedication, and endeavours from the organisation and its workforce – #TeamSAHPRA.
DID YOU KNOW?
- The NSTF is the most representative multi-stakeholder non-profit forum in South Africa (SA) promoting SET and innovation.
- The NSTF-South32 Awards showcase the research and development capacity of our nation.
- The excellent output of the winners supports South Africa’s advancement, economic growth and the social upliftment of people.
- SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting and registering) all health products.
- This includes clinical trials, complementary medicines, medical devices and invitro diagnostics (IVDs).
- Furthermore, SAHPRA has the added responsibility of overseeing radiation control in South Africa.
- SAHPRA’s mandate is outlined in the Medicines and Related Substances Act (Act No 101 of 1965, as amended) as well as the Hazardous Substances Act (Act No 15 of 1973).
- SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa: • Safety • Efficacy • Quality It is these three pillars that define the ethos of SAHPRA.
INFO SUPPLIED.
